Satu Mustjoki
CURRICULUM VITAE
1. Full name
• Mustjoki, Satu Maarit
• Female
• Date of CV 13th March 2015
2. Date and place of birth, nationality, current residence
• January 8th 1972, Lahti, Finland
• Finnish
•
Contact information:
Hematology Research Unit Helsinki
Biomedicum Helsinki
Helsinki University Central Hospital Cancer Center
Haartmaninkatu 8, 00290 Helsinki, Finland
[email protected]
www.helsinki.fi/hematology
+358-9-471-71898 (tel)
+358-9-471-71897 (fax)
3. Education and degrees awarded
•
•
•
•
Adjunct professor (docent), Experimental hematology, University of Helsinki, Finland,
20.04.2011
Specialist in Clinical Chemistry, University of Helsinki, Finland, 28.08.2008
Doctor of Medical Sciences (PhD, Thesis accepted with distinction), University of Helsinki,
Finland, 27.02.2001
Licenciate in Medicine (MD), University of Helsinki, Finland, 30.09.1997
4. Other training, qualifications and skills
•
GCP (good clinical practice) courses related to clinical drug studies
5. Linguistic skills
•
•
•
•
•
Finnish, mother tongue
English, fluent spoken and written skills
Swedish, spoken and written skills in the other official language
German, moderate spoken and written skills
French, basics
6. Current position
•
•
•
•
Research professor for the Finnish Cancer Institute, 1.1.2015Deputy professor in Clinical Chemistry and Hematology (35% position), University of
Helsinki, Finland, 1.3.2015Specialist doctor (5% position), Comprehensive Cancer Center, Helsinki University Central
Hospital, Helsinki, Finland, 1.7.2012Principal investigator (basic research), Hematology Research Unit Helsinki, Biomedicum
Helsinki, Finland 1.8.2007-
1
Satu Mustjoki
•
Research doctor/sub-investigator in Phase I-III clinical studies (in addition to other duties),
Department of Medicine, Division of Hematology, Helsinki University Central Hospital,
Helsinki, Finland, 1.5.2007-
7. Previous work experience
•
•
•
•
•
•
•
•
Senior Academy Research Fellow, Hematology Research Unit Helsinki, Helsinki University
Central Hospital, Helsinki, Finland 1.8.2010-31.12.2014
Academy Clinical Researcher, Hematology Research Unit Helsinki, Helsinki University
Central Hospital, Helsinki, Finland, 1.10.2008-31.7.2010 (grant covered 3 months/year)
Research doctor, Department of Medicine, Division of Hematology, Helsinki University
Central Hospital, Helsinki, Finland, 1.5.2007-31.07.2007
Resident in clinical hematology, Department of Medicine, Division of Hematology, Helsinki
University Central Hospital, Helsinki, Finland, 1.3.-30.4 and 1.9-27.9.07
Doctor assistant and clinical lecturer, Department of Clinical Chemistry, University of
Helsinki, Finland 1.8.2006-31.1.2007
Resident in Clinical Chemistry, Laboratory of Hematology, Helsinki University Central
Hospital, Helsinki, Finland, 1.10.2001-31.03.2002, 1.4.2003-31.7.2006 and 1.2-28.02.2007
Post-Doctoral researcher, Molecular Cancer Biology Program (Group prof. K. Alitalo),
University of Helsinki, Finland, 1.12.2000-30.09.2001
PhD student, Department of Virology (Cancer biology group prof. A. Vaheri), University of
Helsinki, Finland, 1.10.1997-30.11.2000
8. Major recent research funding, academic leadership, and supervision
• European Research Council (ERC) consolidator grant 2015-2020, 2 047 000 eur
• State funding for university level health research 2014-2017, 297 500 eur
• Instrumentarium Science Foundation 2014-2015, 100 000 eur
• Finnish Cancer Organizations, 2015-2016, 100 000 eur
• Nordic Cancer Union, 2013-2015, 240 000 eur
• Finnish Cancer Organizations, 2013-2014, 100 000 eur
• Sigrid Juselius Foundation 2014-2015, 50 000 eur
• Biocentrum Helsinki 2014-2015, 70 000 eur
• Academy of Finland, 2013-2015, 284 168 eur
• Sigrid Juselius Foundation 2010-2013, 144 000 eur
• Academy of Finland (Academy Research fellow) 2010-2015, 391 510 eur
•
Supervision of post-doc researcher (main supervisor):
o PhD Can Hekim 1.4.2012-31.7.2014
o PhD Tiina Kelkka 1.4.2013o MD, PhD Hanna Rajala 1.8.2014o PhD Giljun Park 1.1.2015-
•
PhD thesis supervision:
o M.Sc. Sari Jalkanen (Hernesniemi), University of Helsinki, Finland, 2007-2012
o M.Sc. Anna Kreutzman, University of Helsinki, Finland, 2008-2012 (thesis with honor)
o MD Hanna Rajala (née Koskela), University of Helsinki, Finland, 2010-2014 (thesis
accepted with honorary grade)
o MD Perttu Koskenvesa, University of Helsinki, Finland, 2008- (Title: Off-target effects
of TKI therapy)
2
Satu Mustjoki
o M.Sc. Mette Ilander, University of Helsinki, Finland, 2011- (Title: Antileukemia
immune responses)
o M.Sc. Emma Andersson, University of Helsinki, Finland, 2012- (Title: Characterization
of genetic alterations and novel drug targets in T-cell malignancies)
o M.Sc. Heikki Kuusanmäki, University of Helsinki, Finland, 2012- (Title: Functional role
of STAT3 mutations in LGL leukemia)
o M.Sc. Paavo Pietarinen, University of Helsinki, Finland, 2013- (Title: Ex vivo drug
responses on primary leukemic cells)
o M.Sc. Mohammed ElMissiry, University of Helsinki, Finland, 2013- (Title: Activity of
immune system in children with cancer)
o Med. Student Paula Savola, University of Helsinki, 2013- (Title: The impact of somatic
mutations in lymphocytes in autoimmune disorders)
o Med. Student Olli Dufva, University of Helsinki, 2014- (Title: Anti-tumor immune
effects)
o Med. Student Oscar Bruck, University of Helsinki, 2015- (Title: Therapeutic Cancer
Vaccine in CML as a Model for Effective Immunotherapy)
•
Master’s thesis and MD thesis supervision:
o Mette Ilander, 2010-2011
o Emma Andersson 2011-2012
o Kati Penttinen 2010-2012
o Emmi Vakkila 2011o Jaakko Eskelinen 2012-
9. Merits in teaching and pedagogical competence
• Lecturer in courses associated to Helsinki Biomedical Graduate school and to Specialist
training in Internal Medicine and Clinical Chemistry 2010• Lecturer in CML school organized by CML study group 2010-2013
• Doctor assistant and clinical lecturer, Department of Clinical Chemistry, University of
Helsinki, Finland 1.8.2006-31.1.2007
• Thesis committee member for several PhD students (currently group member in 4 PhD thesis
committees) 201010. Scientific awards, prizes and honours
• Instrumentarium Science foundation fellow award (100 000 eur) 2014
• Senior research fellowship of the Academy of Finland 2010-2015
• Clinical researcher fellowship from the Academy of Finland 2008-2010
• Nomination for the Biocentrum Helsinki research group for years 2014-2016
• One of the 7 research groups of the P-MOLMED (personalized molecular medicine)
consortium which was ranked the number 1 research network in the University of Helsinki
evaluation in 2012 in the category of society impact
• PhD thesis 2001 (Urokinase, Urokinase Receptor, and ICAMs in Human Leukemia) accepted
with distinction
• Best abstract of the XXII Olomouc Hematology Days 2008, Olomouc, Czech Republic
• 2008, 13th Congress of the European Hematology Association, Abstract/travel award,
Copenhagen, Denmark
• 2009, 14th Congress of the European Hematology Association, Abstract/travel award, Berlin,
Germany
• 2011, 16th Congress of the European Hematology Association, Abstract/travel award, London,
UK
3
Satu Mustjoki
•
2012, 54th annual meeting of the American Society of Hematology, The abstract “Discovery of
STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic
(LGL) Leukemia” received the Outstanding Abstract Achievement Award (My PhD student
was the first author and I was the corresponding author), Atlanta, USA
11. Other academic merits
Member of the Editorial board: International Trends in Immunity 2013Member of the Editorial board: Cytokine 2014Board member in the Doctoral programme in clinical research (University of Helsinki) 2013Board member of the Nordic CML study group, 2010Board member of the Finnish Society of Hematology, 2006-2010
Referee in international journals (such as Blood, Leukemia, Haematologica, Blood Cancer
Journal, Future Oncology, Cancers, Acta Haematologica, BioDrugs, Critical Reviews in
Oncology/Hematology, Tumor Biology, Adis Drug Evaluation and Leukemia Research) in
topics related to hematology and immunology, 2001• Pre-examiner of a Doctoral dissertation, University of Oulu, 2014 and University of Helsinki
2015
• Board member of the scientific committee for the 40th Nordic Hematology Spring Meeting 68.5.2009, Tampere, Finland
• Abstract reviewer for the 16th and 18th Congress of the European Hematology Association,
2011 and 2013
• Abstract reviewer for the 54th Congress of the American Society of Hematology, 2014
• External international expert in EU funded project: Innovation of Microscope Morphology
Education in Hematology Using Internet Virtual Interactive Method (CZ.1.07/2.2.00/07.0294),
2008-2010
• Principal investigator or study steering group member in international clinical studies: 3
international, multicenter academic studies run in European countries (http://clinicaltrial.gov
NCT01725204, NCT00852566 and NCT01596114) 2009• Principal investigator in 6 international biomarker discovery programs in association with
clinical drug studies run in European countries 2009• Sub-investigator in 24 international, multicenter clinical studies in hematological malignancies
using novel targeted drugs 2007• International peer evaluation of funding applications:
o Leukemia and Lymphoma Research Foundation (UK)
o Estonian Science Foundation
o L’Oreal Austria (Fellowship application)
• Memberships in professional societies:
o Finnish Medical Association, 1993o Finnish Society of Hematology, 2002o The American Society of Hematology, 2008o The European Society of Hematology, 2008o
12. Scientific and societal impact of research
•
•
•
•
•
•
Altogether, 62 publications which consist of 50 original research journal articles, 10 review articles, 1
chapter in research books and 1 conference proceedings article all of which are published in peerreviewed scientific journals. They have been cited 1587 times (without self-citations) yielding a Hindex of 17. 50/62 of the publications are from the last 6 years.
4
Satu Mustjoki
•
List of 10 most important publications during the last 10 years and their citations
Articles related to LGL leukemia and genetics:
1. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom
S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M,
Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J,
Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP,
Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J
Med 2012;366:1905-13. IF 53.298 (Groundbreaking observation demonstrating that LGL
leukemia is caused by activating STAT3 mutations. Appeared also in Nature Genetics research
highlights and recommended by F1000 Prime. Cited 109 times)
2. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, Andersson EI,
Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K,
Porkka K, Maciejewski JP, Loughran TP, Jr., Heckman C, Mustjoki S. Discovery of somatic
STAT5b mutations in large granular lymphocytic leukemia. Blood 2013 Apr 17. IF 9.060
(This was the first time to discover somatic mutations in STAT5 gene. The mutation type also
correlated with clinical disease phenotype. The article was highlighted in Hematologist and
"This week in Blood" series. Cited 30 times)
3. Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, McGraw K,
Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F,
Lagstrom S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A,
Mufti GJ, List AF, Mustjoki S, Loughran TP, Jr., Maciejewski JP. STAT3-mutations indicate
the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic
syndrome patients. Blood. 2013 Oct 3;122(14):2453-9. IF 9.060 (Discovery of somatic
mutations in patients with AA and MDS, cited 14 times)
4. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E.,
McDonald, T.J., Rajala, H., Ramelius, A., Barton, J., Heiskanen, K., Heiskanen-Kosma, T.,
Kajosaari, M., Murphy, N.P., Milenkovic, T., Seppanen, M., Lernmark, A., Mustjoki, S.,
Otonkoski, T., Kere, J., Morgan, N.G., Ellard, S. & Hattersley, A.T. Activating germline
mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Gen 2014,
46, 812-814. IF 29.648 (Discovery of novel germline STAT3 mutations in patients with multiorgan autoimmune disease)
5. Rajala H, Porkka K, Maciejewski J, Loughran T, Mustjoki S. Uncovering the pathogenesis of
large granular lymphocytic leukemia – novel STAT3 and STAT5b mutations. Ann Med. 2014
May;46(3):114-22. IF 4.733 (Invited review due to significant findings related to STAT5)
Articles related to tumor immunology:
6. Kreutzman, A., Ilander, M., Porkka, K., Vakkila, J. & Mustjoki, S. Dasatinib promotes Th1type responses in granzyme B expressing T-cells. Oncoimmunology 2014, 3, e28925. IF
6.283 (Dual mode of action of TKI therapy; immunomodulation together with oncokinase
inhibition)
7. Kreutzman A*, Ladell K*, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H,
Porkka K, Price DA*, Mustjoki S*, Seggewiss R* (*equal contribution). Expansion of highly
differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with
5
Satu Mustjoki
cytomegalovirus reactivation. Leukemia 2011;25:1587-97. IF 9.561 (Proof of antiviral clonal
T-cells in leukemia patients during TKI therapy. Cited 29 times)
8. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K,
Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia
patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82. IF 9.060
(Discovery of clonal T- and NK-cells in untreated leukemia patients. Cited 56 times)
9. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen
H, Hoglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A,
Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of
T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405.
IF 9.561 (Discovery of clonal LGL expansion as an off-target effect of targeted leukemia
therapy, Cited 116 times)
Articles related to translational studies in clinical trials:
10. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT,
Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevarn B, Olofsson T,
Olsson-Stromberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, HjorthHansen H. Impact of malignant stem cell burden on therapy outcome in newly diagnosed
chronic myeloid leukemia patients. Leukemia 2013 Jul;27(7):1520-6. IF 9.561 (Principal
investigator in this international, randomized clinical drug study, which had the experimental
analysis of leukemia stem cells as a primary study end-point. Cited 4 times)
6